Karolinska Development Valuation
Is 0P3C undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0P3C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0P3C's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0P3C's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0P3C?
Key metric: As 0P3C barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 0P3C's PB Ratio? | |
|---|---|
| PB Ratio | 0.2x |
| Book | SEK 1.22b |
| Market Cap | SEK 285.48m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 137.7x |
| Enterprise Value/EBITDA | -9.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 0P3C's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.4x | ||
POLB Poolbeg Pharma | 2.9x | -13.1% | UK£36.3m |
EAH ECO Animal Health Group | 0.5x | 34.2% | UK£44.4m |
REDX Redx Pharma | 17.4x | -22.3% | UK£58.3m |
STX Shield Therapeutics | 52.6x | 84.6% | UK£22.7m |
0P3C Karolinska Development | 0.2x | 5.8% | SEK 285.5m |
Price-To-Book vs Peers: 0P3C is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (18.4x).
Price to Book Ratio vs Industry
How does 0P3C's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 4 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 2.3x | 19.6% | |
0P3C Karolinska Development | 0.2x | 5.8% | US$25.96m |
EAH ECO Animal Health Group | 0.5x | 34.2% | US$55.67m |
OCTP Oxford Cannabinoid Technologies Holdings | 0.6x | 15.1% | US$1.60m |
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 2.3x | 19.6% | |
0P3C Karolinska Development | 0.2x | 5.8% | US$25.96m |
Price-To-Book vs Industry: 0P3C is good value based on its Price-To-Book Ratio (0.2x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 0P3C's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 0P3C's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
hVIVO
UK£134.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.20
7D
-16.8%
1Y
2.1%
Formycon
€844.9m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.35
7D
2.8%
1Y
-24.9%
Regeneron Pharmaceuticals
US$80.6b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$750.19
7D
0.5%
1Y
-5.7%